Samsung Bioepis launches SB17, a biosimilar of Johnson & Johnson's Stelara for autoimmune diseases, in Japan through partner Nipro Corporation, marking its first biosimilar entry into the Japanese market while already selling the product as Pyzchiva in Europe and the US, and Epiztek in South Korea.
#YonhapInfomax #SamsungBioepis #Biosimilar #SB17 #JapanMarket #AutoimmuneDisease #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=121456